Inicio › Cáncer de pulmón de células no pequeñas › Illinois

Ensayos clínicos de Cáncer de pulmón de células no pequeñas en Illinois

91 estudios sobre Cáncer de pulmón de células no pequeñas buscan participantes en Illinois.

Ciudades en Illinois

Texto oficial del estudio (inglés)

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

University of Illinois Chicago, Chicago
Illinois Cancer Specialists, Niles

ReclutandoFase 3

Edades de 18 a 100 · Todos los sexos · Actualizado el 13 nov 2026 · NCT05920356

A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer

University of Chicago, Chicago

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 13 nov 2026 · NCT07659782

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-based Chemotherapy With or Without Amivantamab for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

Rush University Medical Center, Chicago

ReclutandoFase 2/3

Edades de 18 en adelante · Todos los sexos · Actualizado el 12 nov 2026 · NCT07100080

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

Endeavor Health, Elmhurst
Hope and Healing Cancer Services, Hinsdale
Advocate Medical Group - Libertyville Oncology, Libertyville
y 4 más

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 12 nov 2026 · NCT06758401

A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)

Duly Healthcare ( Site 0158), Lisle

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 12 nov 2026 · NCT07554339

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

Northwestern University, Chicago
Northwestern Medicine Cancer Center Kishwaukee, DeKalb
Northwestern Medicine Cancer Center Delnor, Geneva
y 8 más

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 12 nov 2026 · NCT06498635

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

Advocate Good Shepherd Hospital, Barrington
Illinois CancerCare-Bloomington, Bloomington
Illinois CancerCare-Canton, Canton
y 42 más

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 12 nov 2026 · NCT04267848

A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)

Orchard Healthcare Research Inc. ( Site 0115), Skokie

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 12 nov 2026 · NCT06345729

Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor

University of Illinois Cancer Center, Chicago

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 12 nov 2026 · NCT06472245

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

North Shore University Health System ( Site 4014), Evanston
Accellacare of Duly ( Site 4005), Lisle

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 10 nov 2026 · NCT06312137

Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)

Local Institution - 0185, Chicago
Local Institution - 0207, Ottawa

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 10 nov 2026 · NCT07680790

Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

Research Site, Chicago
Research Site, Chicago
Research Site, Hinsdale
y 2 más

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 10 nov 2026 · NCT07291037

LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC

Northwest Oncology & Hematology, Barrington
Elmhurst Hospital Nancy Knowles Cancer Center, Elmhurst
Edward Cancer Center, Naperville
y 1 más

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 10 nov 2026 · NCT06216301

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

The University of Chicago Medical Center ( Site 0118), Chicago
Illinois Cancer Care ( Site 8107), Peoria

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 9 nov 2026 · NCT06623422

A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)

Illinois Cancer Care ( Site 7000), Peoria

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 9 nov 2026 · NCT07513376

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

University of Illinois Cancer Center, Chicago

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 6 nov 2026 · NCT04198766

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

Illinois Cancer Specialists, Arlington Heights
Illinois CancerCare- Bloomington, Bloomington
Illinois Cancer Specialists, Chicago
y 7 más

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 5 nov 2026 · NCT07144280

Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial

Illinois CancerCare-Bloomington, Bloomington
Illinois CancerCare-Canton, Canton
Illinois CancerCare-Carthage, Carthage
y 24 más

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 5 nov 2026 · NCT07388524

A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

Affiliated Oncologists, LLC, Chicago Ridge
City of Hope® Cancer Center Chicago, Zion

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 5 nov 2026 · NCT06793215

A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

University of Chicago Medical Center, Chicago
Endeavor Health, Evanston
Illinois Cancer Care, Peoria

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 5 nov 2026 · NCT07361497

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

University of Chicago Hospital, Chicago

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 4 nov 2026 · NCT06465069

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

City of Hope, Chicago, Chicago
University of Illinois at Chicago, Chicago
University of Chicago Medical Center, Chicago
y 3 más

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 4 nov 2026 · NCT06890598

A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations

Northwestern Medicine - Northwestern Memorial Hospital Galter Pavilion, Chicago

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 4 nov 2026 · NCT06706076

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

OSF Saint Anthony's Health Center, Alton
Rush-Copley Medical Center, Aurora
Advocate Outpatient Center - Aurora, Aurora
y 45 más

ReclutandoEstudio observacional

Edades de 18 en adelante · Todos los sexos · Actualizado el 4 nov 2026 · NCT06418204

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

University of Illinois at Chicago, Chicago
University of Chicago Hospital, Chicago
Springfield Clinic Main Campus, Springfield

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 4 nov 2026 · NCT06119581

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

City of Hope Chicago, Zion

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 3 nov 2026 · NCT06667076

Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

OSF Saint Anthony's Health Center, Alton
Illinois CancerCare-Bloomington, Bloomington
Illinois CancerCare-Canton, Canton
y 31 más

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 3 nov 2026 · NCT03191149

A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment

OSF Saint Joseph Medical Center, Bloomington
Illinois CancerCare-Bloomington, Bloomington
Illinois CancerCare-Canton, Canton
y 19 más

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 3 nov 2026 · NCT07293247

A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.

OSF Saint Francis Medical Center, Peoria

ReclutandoFase 2/3

Edades de 18 en adelante · Todos los sexos · Actualizado el 3 nov 2026 · NCT07365319

Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

Illinois Cancer Specialists, Arlington Heights
University of Illinois Hospital and Health Sciences Systems, Chicago

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 2 nov 2026 · NCT07185997

Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations

Northwestern University, Chicago
University of Illinois Hospital and Health Sciences System, Chicago
Duly Health and Care - Lisle, Lisle

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 2 nov 2026 · NCT07195695

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

Local Institution - 007-883-A, Arlington Heights
University of Chicago, Chicago
Loyola University Medical Center, Maywood
y 2 más

ReclutandoFase 2/3

Edades de 18 en adelante · Todos los sexos · Actualizado el 30 oct 2026 · NCT04613596

Study of XB010 in Subjects With Solid Tumors

University of Chicago Medical Center, Chicago

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 30 oct 2026 · NCT06545331

Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers

University of Chicago, Chicago

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 29 oct 2026 · NCT05098132

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

Research Site, Chicago
Research Site, Decatur
Research Site, Hinsdale
y 1 más

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 29 oct 2026 · NCT06692738

Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

University of Chicago Medical Center ( Site 0145), Chicago

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 29 oct 2026 · NCT06422143

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

Research Site, Hinsdale

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 28 oct 2026 · NCT06357533

Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations

Hope And Healing Cancer Services /ID# 276223, Hinsdale

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 27 oct 2026 · NCT06772623

A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

Illinois Cancer Specialists, Arlington Heights
University of Illinois at Chicago, Chicago
Springfield Clinic Main Campus, Springfield

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 27 oct 2026 · NCT06875310

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

University of Illinois Cancer Center, Chicago

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 26 oct 2026 · NCT06172478

De ClinicalTrials.gov, datos obtenidos el 15 nov 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.